Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transthyretin-Mediated Amyloidosis”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Testing effectiveness (Phase 2)Study completedNCT02595983
What this trial is testing

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Who this might be right for
Transthyretin (TTR)-Mediated AmyloidosisFamilial Amyloidotic Polyneuropathy (FAP)ATTR Amyloidosis+1 more
Alnylam Pharmaceuticals 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04136171
What this trial is testing

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. 1,438
Not applicableLooking for participantsNCT04561518
What this trial is testing

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Who this might be right for
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals 1,500
Not applicableActive Not RecruitingNCT06073574
What this trial is testing

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 150
Large-scale testing (Phase 3)WithdrawnNCT04418024
What this trial is testing

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Large-scale testing (Phase 3)Looking for participantsNCT06672237
What this trial is testing

NTLA-2001 in ATTRv-PN

Who this might be right for
Neuromuscular DiseaseNeuromuscular Diseases (NMD)Neurodegenerative Disease+17 more
Intellia Therapeutics 60
Large-scale testing (Phase 3)Enrolling By InvitationNCT05667493
What this trial is testing

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. 1,400
Early research (Phase 1)Study completedNCT06527755
What this trial is testing

Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

Who this might be right for
Transthyretin-mediated Amyloidosis
AstraZeneca 12
Post-approval studies (Phase 4)Ended earlyNCT04306510
What this trial is testing

Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

Who this might be right for
Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics 8
Not applicableLooking for participantsNCT05040373
What this trial is testing

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Who this might be right for
Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy
Alnylam Pharmaceuticals 10
Testing effectiveness (Phase 2)Study completedNCT03728634
What this trial is testing

Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

Who this might be right for
Healthy VolunteershATTR Amyloidosis
Ionis Pharmaceuticals, Inc. 47
Not applicableLooking for participantsNCT06465810
What this trial is testing

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Who this might be right for
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca 1,850
Large-scale testing (Phase 3)Study completedNCT03862807
What this trial is testing

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Who this might be right for
Amyloidosis, FamilialTransthyretin Amyloidosis
Alnylam Pharmaceuticals 24
Not applicableNot Yet RecruitingNCT07591038
What this trial is testing

PET/CT Imaging in Carriers of TTR Mutations

Who this might be right for
ATTRATTR Gene MutationCardiomyopathy+1 more
University of Texas Southwestern Medical Center 80
Not applicableActive Not RecruitingNCT06073587
What this trial is testing

The CARDIO-TTRansform Scintigraphy Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 150
Large-scale testing (Phase 3)Looking for participantsNCT07052903
What this trial is testing

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals 1,250
Large-scale testing (Phase 3)Study completedNCT02510261
What this trial is testing

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
Amyloidosis
Alnylam Pharmaceuticals 211
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Large-scale testing (Phase 3)Enrolling By InvitationNCT06679946
What this trial is testing

Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 700
Not applicableActive Not RecruitingNCT06360289
What this trial is testing

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Who this might be right for
Hereditary Amyloidosis, Transthyretin-RelatedAsymptomatic Carrier State
Alnylam Pharmaceuticals 346
Load More Results